CRBU Caribou Biosciences, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1619856 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.6%
TTM net income YoY34.8%
TTM EPS YoY39.4%
Revenue 3-yr CAGR-35.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,140.6%
Net margin-1,085.0%
FCF margin-984.6%
EBITDA margin-1,113.6%
Returns
ROE-93.8%
ROA-64.4%
ROIC (approx.)-93.9%
Asset turnover0.06x
Leverage & solvency
Liabilities / assets37.7%
Debt / equity0.00x
Current ratio4.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.91x
Accruals ratio-5.9%
Payout ratio—
Capex / revenue-1.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $11.16M | $9.99M |
| R&D expense | $109.44M | $130.15M |
| SG&A expense | $37.91M | $46.46M |
| Operating income | -$148.34M | -$166.62M |
| Pretax income | -$148.68M | -$149.11M |
| Income tax | -$550,000 | -$9,000 |
| Net income | -$148.12M | -$149.10M |
| EBITDA | -$144.70M | -$162.69M |
| EPS (basic) | -1.59 | -1.65 |
| EPS (diluted) | -1.59 | -1.65 |
| Weighted avg. shares (diluted) | 93.39M | 90.32M |
| Balance sheet | ||
| Cash & equivalents | $12.36M | $16.34M |
| Short-term investments | $126.98M | $193.24M |
| Receivables | $69,000 | $265,000 |
| Current assets | $145.23M | $219.38M |
| PP&E, net | $6.76M | $19.28M |
| Total assets | $175.37M | $313.31M |
| Current liabilities | $25.41M | $30.65M |
| Total liabilities | $53.19M | $60.36M |
| Shareholders' equity | $122.17M | $252.95M |
| Shares outstanding | 95.14M | 92.38M |
| Cash flow statement | ||
| Operating cash flow | -$110.99M | -$138.20M |
| Capital expenditure | $1.36M | $4.88M |
| Free cash flow | -$112.35M | -$143.08M |
| Investing cash flow | $102.24M | $86.61M |
| Financing cash flow | $4.82M | $16.72M |
| Depreciation & amortization | $3.65M | $3.93M |
| Stock-based compensation | $12.68M | $16.71M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.